Novacyt (XPAR:ALNOV) Change In Payables And Accrued Expense : €0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Novacyt Change In Payables And Accrued Expense?

Novacyt's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2023 was €0.00 Mil. It means Novacyt's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Jun. 2023 .

Novacyt's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2022 was €0.00 Mil. It means Novacyt's Accounts Payable & Accrued Expense stayed the same from Dec. 2021 to Dec. 2022 .

Novacyt Change In Payables And Accrued Expense Historical Data

The historical data trend for Novacyt's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novacyt Change In Payables And Accrued Expense Chart

Novacyt Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Novacyt Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Novacyt Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Novacyt Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Novacyt's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Novacyt (XPAR:ALNOV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Novacyt SA (XPAR:ALNOV) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

NVYTF:USA NCYT:UK NYZ:Germany

Address

13, Avenue Morane Saulnier, Velizy-Villacoublay, FRA, 78140

Website

https://www.novacyt.com

Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.

Novacyt (XPAR:ALNOV) Headlines

No Headlines